{
  "docId": "019de070-1001-704a-89ab-d7496f4fd716",
  "docSlug": "51e89351998d2fd4ac099e485858473c",
  "documentTitle": "BioNTech | Results Presentation Deck | 11 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 11,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "Includes footnote regarding currency conversion rate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1001-704a-89ab-d7496f4fd716/9",
  "deckHref": "/decks/019de070-1001-704a-89ab-d7496f4fd716",
  "deckJsonHref": "/decks/019de070-1001-704a-89ab-d7496f4fd716.json",
  "deckAnchorHref": "/decks/019de070-1001-704a-89ab-d7496f4fd716#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "Cash and cash equivalents of EUR 452m (USD 495m) as of March 31, 2020. Additional EUR 217m (USD 236m) due in 2Q 2020 from Pfizer and Fosun Pharma. Net cash used in operating activities and investments on track. Majority of BNT162 development costs funded via partners.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96e8af85-1805-4961-a0f8-44b1c5b44f3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.15,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1 Rate German Central Bank as of March 31, 2020",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "096b2a01-e038-41b6-97ba-9ae857b5e2a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.7,
        "x": 0.15,
        "y": 0.465
      },
      "kind": "table",
      "text": "P&L statement comparing Q1 2020 and Q1 2019 figures for revenues, costs, and expenses.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9484bd89-d821-4073-ac41-5af16920a0c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "First Quarter 2020 Financial Results (unaudited) – Profit and Loss",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ea378e4-3c1b-43f5-98b0-79de772c0e43",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "d14cff82-4b05-4d68-9a07-29a262a448af",
      "evidence": "table/data: P&L statement comparing Q1 2020 and Q1 2019 figures for revenues, costs, and expenses.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "6aac014e-1e66-4bcd-9b88-0aa03bf54131",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "Slide 9 provides an overview of Q1 2020 financial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    },
    {
      "to": 10,
      "from": 4,
      "beatId": "a1e10f88-6e5d-473c-a25a-cabcc03d02ec",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "Slides 4 and 10 provide key takeaways on the COVID-19 program and building a next-generation immunotherapy company.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}